Lower incidence of hepatocellular carcinoma with tenofovir alafenamide in chronic hepatitis B: Evidence from a large-scale cohort
Background & Aims: Tenofovir alafenamide (TAF) lacks extensive research regarding its impact on hepatocellular carcinoma (HCC). This study evaluated and compared the effects of TAF, tenofovir disoproxil fumarate (TDF), and entecavir (ETV) on HCC incidence using nationwide claim data. Methods...
Saved in:
Main Authors: | Hye-Jin Yoo, Jae-Young Kim, Jeong-Ju Yoo, Hye Won Lee, Sang Gyune Kim, Young Seok Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-02-01
|
Series: | JHEP Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2589555924002726 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Long-Term Real-World Outcomes of Tenofovir Alafenamide in Chronic Hepatitis B: Detailed Analysis of Treatment-Naive and Experienced Patients
by: Yu-Xuan Song, et al.
Published: (2025-01-01) -
Nucleoside analogues in treatment of liver cirrhosis as an outcome of chronic hepatitis B
by: I. G. Bakulin
Published: (2009-02-01) -
Effect of potent nucleos(t)ide analog on alpha fetoprotein changes and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B
by: Qianqian Ma, et al.
Published: (2025-02-01) -
Weight Change and Predictors of Weight Change Among Patients Initiated on Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide or Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Real-World Retrospective Study
by: Bruno Emond, et al.
Published: (2021-06-01) -
Potentials of antiviral therapy at patients with liver cirrhosis in an outcome of HCV-infection
by: E. N. Bessonova
Published: (2011-06-01)